Entera Bio Ltd. EPS (Basic, from Continuous Ops)

EPS (Basic, from Continuous Ops) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Basic, from Continuous Ops) growth rates and interactive chart.


Highlights and Quick Summary

  • EPS (Basic, from Continuous Ops) for the quarter ending June 29, 2020 was -0.17 (a 8.16% increase compared to previous quarter)
  • Year-over-year quarterly EPS (Basic, from Continuous Ops) decreased by -29.65%
  • Annual EPS (Basic, from Continuous Ops) for 2019 was -0.89 (a -31.39% decrease from previous year)
  • Annual EPS (Basic, from Continuous Ops) for 2018 was -1.3 (a -48.05% decrease from previous year)
  • Twelve month EPS (Basic, from Continuous Ops) ending June 29, 2020 was -0.85 (a 7.43% increase compared to previous quarter)
  • Twelve month trailing EPS (Basic, from Continuous Ops) increased by 6.66% year-over-year
Trailing EPS (Basic, from Continuous Ops) for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-0.85 -0.79 -0.89 -0.79
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Basic, from Continuous Ops) of Entera Bio Ltd.

Most recent EPS (Basic, from Continuous Ops)of ENTX including historical data for past 10 years.

Interactive Chart of EPS (Basic, from Continuous Ops) of Entera Bio Ltd.

Entera Bio Ltd. EPS (Basic, from Continuous Ops) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -0.17 -0.16
2019 -0.26 -0.25 -0.12 -0.26 -0.89
2018 -0.17 -0.45 0.35 -0.93 -1.3
2017 -2.49

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.